Core Points - Catheter Precision, Inc. announced that its audited financial statements for the year ended December 31, 2024, included an audit opinion with a Substantial Doubt Regarding Going Concern paragraph [1] - This announcement complies with NYSE American Company Guide Section 610(b), which mandates a separate public announcement for audit opinions containing a going concern paragraph [2] Financial Information - The audit opinion indicating substantial doubt about the company's ability to continue as a going concern was disclosed in the Annual Report on Form 10-K filed on March 31, 2025 [1] - The announcement does not alter the company's consolidated financial statements or its Annual Report on Form 10-K for the year ended December 31, 2024 [2]

NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received a notice of allowance from the US Patent Office of its first patent in the US for its LockeT product, filed in December 2022, for its design of a surgical closure device for orthoscopic entry wounds. David Jenkins, CEO of Catheter Precision, commented, "This first US patent for LockeT joins our other issued international LockeT pate ...

Financial Performance - Total assets as of December 31, 2024, were $27.7 million[7] - Total shareholders' equity as of December 31, 2024, was $11.8 million[7] - Fourth quarter revenue was $149 thousand, representing a sequential increase of 55% over Q3 2024[7] - Full year 2024 revenue totaled $420 thousand[7] - Net loss for the fourth quarter was $5.6 million, with $3.1 million attributed to non-cash charges[7] - Total net loss for 2024 was $16.6 million, of which $7.5 million were non-cash charges[7] Product Development and Sales - The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year[1] - 26 institutions evaluated LockeT by year-end, either conducting or having completed their evaluations[1] - CE Mark for LockeT is anticipated in Q2 2025, allowing sales in 32 European countries[1] - Randomized Controlled Trial (RCT) for VIVO is planned to begin in Q3 2025[1]

FORM 10-K Table of Contents For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant as specified in its charter) (State or other jurisdiction ...

FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was c ...

Financial Highlights - Catheter Precision reported total assets of $27.7 million and total shareholders' equity of $11.8 million as of December 31, 2024 [3] - The company had 8,004,633 outstanding shares of common stock by the end of 2024 [3] - Fourth quarter revenue reached $149 thousand, marking a sequential increase of 55% over Q3 2024, while full year 2024 revenue totaled $420 thousand [3] - The net loss for the fourth quarter was $5.6 million, with $3.1 million attributed to non-cash charges; total net loss for 2024 was $16.6 million, including $7.5 million in non-cash charges [3] Operational Updates - A new Chief Commercial Officer joined in Q2 2024, leading to a significant overhaul of the sales team [3] - The first sales of the LockeT device occurred in Q2 2024, with sales growing sequentially each quarter [3] - By year-end 2024, 26 hospitals had evaluated the LockeT device through surgical procedures [3] - The company completed audits for LockeT's CE Mark in Q4 2024, with expectations to receive the CE Mark in Q2 2025, allowing sales in 32 European countries starting Q3 2025 [3] - VIVO marketing and sales efforts are ongoing in the US and several international markets, including Germany, Turkey, and the UK [3] Clinical Studies and Publications - Two clinical studies were published in 2024, focusing on non-invasive mapping systems and the combination of cardiac imaging with electrocardiographic information [3] - The first LockeT journal manuscript and two abstracts were published in 2024, detailing the feasibility, safety, and efficacy of the LockeT device [3] - Additional clinical studies for both VIVO and LockeT are ongoing or planned for 2025, including a Randomized Controlled Trial (RCT) for VIVO set to begin in Q3 2025 [3]

FORT MILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at three upcoming conferences through April 2, 2025. Catheter Precision will be attending the following conferences: American College of Cardiology (ACC) from March 29-31, 2025, in Chicago, IllinoisEuropean Heart Rhythm Association (EHRA) March 30 – Apr ...

FORT MILL, S.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah. Western AF is an internationally recognized meeting focused on improving atrial fibrillation (AF) outcomes worldwide. Led by more than 80 world-renowned ...

BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts. By partnering with PCG Advisory, Catheter Preci ...

FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas. The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial ...